Last deal

$150M

Amount

Series E

Stage

20.02.2019

Date

3

all rounds

$242.6M

Total amount

date founded

Financing round

General

About Company
Peloton Therapeutics is a biopharmaceutical company developing cancer drugs.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2010

Number of employees

Company Type

For Profit

Last funding type

Series E

IPO status

Private

Description

Founded by Steven L. McKnight, Peloton Therapeutics combines innovative science, financial support from CPRIT, and experienced investors to advance its small molecule-based programs targeting HIF-2α, a previously challenging transcription factor. Their drug candidate, PT2977, has shown promise in treating advanced clear cell renal cell carcinoma.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Kolltan Pharmaceuticals

Kolltan Pharmaceuticals

Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Internet, Pharmaceuticals

Location

New Haven, CT, USA

total rounds

6

total raised

$146M
Kazia Therapeutics

Kazia Therapeutics

Kazia Therapeutics is an oncology-focused biotech company developing innovative anti-cancer drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Clinical Trials, Health Care

Location

Hornsby NSW 2077, Australia

total rounds

4

total raised

$10.79M
OncoMed Pharmaceuticals

OncoMed Pharmaceuticals

OncoMed Pharmaceuticals develops monoclonal antibodies that target cancer stem cells for improved cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Redwood City, CA, USA

total rounds

4

total raised

$210.15M
Seak Therapeutics

Seak Therapeutics

SEAK Therapeutics is a biotech company focused on developing precision cancer treatment drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Memphis, TN, USA
M&A Details
1

Acquired by

Merck Sharp & Dohme Sweden AB

announced date

21.05.2019

Financials

Funding Rounds
4
3

Number of Funding Rounds

$242.6M

Money Raised

Their latest funding was raised on 20.02.2019. Their latest investor Regents of the University of California. Their latest round Series E

Date 
Funding Round 
Investors 
Money Raised 
Lead 
14.03.2017
$22.2M
15.09.2016
5
$52.4M
RA Capital Management

RA Capital Management

RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services

Location

Boston, MA, USA

count Of Investments

381

count Of Exists

33
Co-Investors
Investors
15
1

Number of lead investors

15

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series E
No
Series D
Regents of the University of California

Regents of the University of California

The Regents of the University of California govern a public university system.

Sector

Consumer Services

Subsector

Education Services

Keywords

Education, University, Higher Education

Location

Oakland, CA, USA

total rounds

8

total raised

$1.17M

count Of Investments

4

count Of Exists

1
curative ventures

curative ventures

Curative Ventures is a venture capital firm that partners with biotech companies to develop innovative therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dallas, TX, USA

count Of Investments

4

count Of Exists

1

Topspin Fund

Topspin Fund

count Of Investments

7

count Of Exists

1

People

Founders
2
Steven McKnight
Steven McKnight

Steven McKnight

current job

University of Texas Southwestern Medical School
University of Texas Southwestern Medical School

organization founded

4

Steven McKnight

Michael S. Brown
Michael S. Brown

Michael S. Brown

Dr. Brown is Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at the University of Texas Southwestern Medical School in Dallas. He and his long-time colleague, Dr. Joseph L. Goldstein, together discovered the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. They showed that mutations in this receptor cause Familial Hypercholesterolemia, a disorder that leads to premature heart attacks in one out of every 500 people in most populations. They have received many awards for this work, including the Nobel Prize for Medicine or Physiology (1985), the Albert D. Lasker Prize in Basic Medical Research (1985) and the U.S. National Medal of Science (1988). Dr. Brown is a member of the Board of Directors of Pfizer and Regeneron and a former member of the Science Advisory Board of Genentech. He is also a member of the National Academy of Sciences, the Institute of Medicine, Royal Society (London), the Association of American Physicians and the American Society for Clinical Investigation.

current job

The Column Group
The Column Group

Michael S. Brown

Employee Profiles
15

Eric Park

Senior director, clinical development

Robert Sprague

Project manager

Paul Wehn

Senior scientist

Peter Stengel

Director, chemical development

James P. Rizzi

James P. Rizzi

VP of Computational Technology

Mohammad Hirmand

Mohammad Hirmand

Chief Medical Officer

Michael S. Brown

Michael S. Brown

Founder and Director

Steven McKnight

Steven McKnight

Founder

Activity

Recent News
0